I have also been thinking about whether GiveWell/other donors will fill the funding needs at AMF and I should look for something in between AMF and GiveDirectly that needs funding.
1 Day Sooner (promoting greater use of Human Challenge Trials for vaccine development) is the global health group I’m personally most excited about. I would personally probably invest money in them over AMF if I was doing global health donations even if AMF is funding constrained, though I’d want to think carefully about both 1 Day Sooner and AMF if I was advising or donating considerable amounts of money in global health.
Note that both subcause areas are less well-studied and higher uncertainty than AMF. I’m not aware of Pareto improvements to AMF along the risk to cost-effectiveness frontier.
I have also been thinking about whether GiveWell/other donors will fill the funding needs at AMF and I should look for something in between AMF and GiveDirectly that needs funding.
1 Day Sooner (promoting greater use of Human Challenge Trials for vaccine development) is the global health group I’m personally most excited about. I would personally probably invest money in them over AMF if I was doing global health donations even if AMF is funding constrained, though I’d want to think carefully about both 1 Day Sooner and AMF if I was advising or donating considerable amounts of money in global health.
I also feel fairly optimistic about lead reduction, based on this Rethink Priorities report.
Note that both subcause areas are less well-studied and higher uncertainty than AMF. I’m not aware of Pareto improvements to AMF along the risk to cost-effectiveness frontier.